NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 120 filers reported holding NURIX THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $186,730 | -17.1% | 23,757 | +5.3% | 0.00% | 0.0% |
| Q2 2023 | $225,304 | +13.3% | 22,553 | +0.7% | 0.00% | 0.0% |
| Q1 2023 | $198,868 | -17.5% | 22,395 | +2.0% | 0.00% | -50.0% |
| Q4 2022 | $241,000 | -16.0% | 21,949 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $287,000 | +9.1% | 22,028 | +6.1% | 0.00% | 0.0% |
| Q2 2022 | $263,000 | +20.6% | 20,752 | +33.5% | 0.00% | +100.0% |
| Q1 2022 | $218,000 | -54.8% | 15,550 | -6.6% | 0.00% | -50.0% |
| Q4 2021 | $482,000 | -6.2% | 16,644 | -2.9% | 0.00% | -33.3% |
| Q3 2021 | $514,000 | +10.3% | 17,142 | -2.3% | 0.00% | +50.0% |
| Q2 2021 | $466,000 | +7.4% | 17,550 | +25.8% | 0.00% | 0.0% |
| Q1 2021 | $434,000 | +94.6% | 13,953 | +106.0% | 0.00% | +100.0% |
| Q4 2020 | $223,000 | -3.9% | 6,772 | +2.0% | 0.00% | 0.0% |
| Q3 2020 | $232,000 | – | 6,641 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |